Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Extends Research Deal with UBC, AlCana

Premium

Alnylam Pharmaceuticals said this week that it has extended its lipid delivery-technology collaboration with the University of British Columbia and Canadian firm AlCana Technologies for a third year.

The research collaboration is funded by Alnylam and the work will be conducted by scientists at UBC and AlCana.

Under the terms of the research alliance, which was forged in 2009, Alnylam has the exclusive rights to all new inventions in the RNAi field, as well as rights to sublicense any resulting intellectual property to Alnylam's current and future partners.

As part of the original agreement, Tekmira Pharmaceuticals receives the rights to use any new AlCana/UBC inventions for its own RNAi therapeutic programs licensed under Alnylam intellectual property.

The Scan

Alzheimer's Risk Gene Among Women

CNN reports that researchers have found that variants in MGMT contribute to Alzheimer's disease risk among women but not men.

Still Hanging Around

The Guardian writes that persistent pockets of SARS-CoV-2 in the body could contribute to long COVID.

Through a Little Spit

Enteric viruses like norovirus may also be transmitted through saliva, not just the fecal-oral route, according to New Scientist.

Nature Papers Present Method to Detect Full Transcriptome, Viruses Infecting Asgard Archaea, More

In Nature this week: VASA-seq approach to detect full transcriptome, analysis of viruses infecting Asgard archaea, and more.